These 10 Stocks Were Wednesday’s Worst Performers

2. Teva Pharmaceuticals Industries Ltd. (NYSE:TEVA)

Teva Pharmaceuticals’ share prices declined by 13.89 percent on Wednesday to finish at $18.54 each after announcing disappointing earnings guidance for 2025.

Prior to market opening, Teva announced a 3.8-percent increase in revenues to $16.5 billion from the $15.9 billion year-on-year fueled by strong sales in medications for migraines, Huntington’s disease, and schizophrenia.

However, Teva expected lower projections for earnings per share for the year at between $2.35 to $2.65 versus the $2.76 projected by analysts.

According to analysts, the positive revenue growth was not enough to outweigh guidance for 2025.

Teva, however, said it remains committed to its “Pivot to Growth” strategy, emphasizing a reorganization and a strengthened focus on generic medications.

In addition, it plans to resume research and development efforts, particularly in key drugs for ulcerative colitis and Crohn’s disease which it expects to be pivotal in shaping the company’s growth trajectory.